Aspirina Fecofar may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspirina Fecofar in the following countries:
International Drug Name Search
Phoenix Pharmacillin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Benzylpenicillin procaine (a derivative of Benzylpenicillin) is reported as an ingredient of Phoenix Pharmacillin in the following countries:
International Drug Name Search
Budesonid acis may be available in the countries listed below.
Budesonide is reported as an ingredient of Budesonid acis in the following countries:
International Drug Name Search
Propolipid may be available in the countries listed below.
Propofol is reported as an ingredient of Propolipid in the following countries:
International Drug Name Search
Polycarbophil Calcium may be available in the countries listed below.
Polycarbophil Calcium (BANM) is known as Polycarbophil in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
Ciprofloxacine ActavisGroup may be available in the countries listed below.
Ciprofloxacin lactate (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacine ActavisGroup in the following countries:
International Drug Name Search
Ipramol Steri-Nebs may be available in the countries listed below.
Ipratropium Bromide is reported as an ingredient of Ipramol Steri-Nebs in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Ipramol Steri-Nebs in the following countries:
International Drug Name Search
Primol may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Primol in the following countries:
International Drug Name Search
Pinavérium Ratiopharm may be available in the countries listed below.
Pinaverium Bromide is reported as an ingredient of Pinavérium Ratiopharm in the following countries:
International Drug Name Search
A.A. Leva may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of A.A. Leva in the following countries:
International Drug Name Search
Meticel Ofteno may be available in the countries listed below.
Hypromellose is reported as an ingredient of Meticel Ofteno in the following countries:
International Drug Name Search
Class: Neuromuscular Blocking Agents
VA Class: MS300
CAS Number: 15500-66-0
Brands: Pavulon
Should be administered only by individuals experienced in the use of neuromuscular blocking agents.a
Nondepolarizing neuromuscular blocking agent.a
Production of skeletal muscle relaxation during surgery after general anesthesia has been induced.a
Facilitation of endotracheal intubation.a
Treatment to increase pulmonary compliance during assisted or controlled respiration.a
Adjust dosage carefully according to individual requirements and response.a
Assess neuromuscular blockade and recovery in patients undergoing anesthesia; a peripheral nerve stimulator is recommended to accurately monitor the degree of muscle relaxation and to minimize the possibility of overdosage.a
To avoid patient distress, administer only after unconsciousness has been induced.a b c
Endotracheal intubation generally can be performed within 2–3 minutes following administration of 0.06-mg/kg dose.a (See Onset and also Duration under Pharmacokinetics.)
Supplemental doses to maintain muscle relaxation increase magnitude and duration of neuromuscular blockade.a
To reverse neuromuscular blockade, administer a cholinesterase inhibitor (e.g., neostigmine, pyridostigmine, edrophonium), usually in conjunction with an antimuscarinic (e.g., atropine, glycopyrrolate) to block adverse muscarinic effects of the cholinesterase inhibitor.a c
For solution and drug compatibility information, see Compatibility under Stability.
Administer IV only; administer initial (intubating) dose by rapid IV injection.a
Consult specialized references for specific procedures and techniques of administration.b
Available as pancuronium bromide; dosage expressed in terms of the salt.a
Children >1 month of age: 0.04–0.1 mg/kg as adjunct to balanced anesthesia.a 0.06–0.1 mg/kg is recommended for endotracheal intubation.a (See Onset and also Duration under Pharmacokinetics.)
If administering following succinylcholine and/or maintenances doses of inhalation anesthetics (e.g., enflurane, halothane, isoflurane), use dosage at lower end of recommended initial range.a Administer after effects of succinylcholine subside.a
Neonates ≤1 month of age: Administer test dose of 0.02 mg/kg to determine responsiveness.a
Children 3 months to 12 years of age: 0.01 mg/kg administered at 25- to 60-minute intervals to maintain skeletal muscle relaxation during prolonged surgery or assisted respiration;a b 0.015 mg/kg may be used to maintain relaxation for controlled respiration.b
0.04–0.1 mg/kg as adjunct to balanced anesthesia.a 0.06–0.1 mg/kg is recommended for endotracheal intubation.a (See Onset and also Duration under Pharmacokinetics.)
If administering following succinylcholine and/or maintenances doses of inhalation anesthetics (e.g., enflurane, halothane, isoflurane), use dosage at lower end of recommended initial range.a Administer after effects of succinylcholine subside.a
0.01 mg/kg administered at 25- to 60-minute intervals to maintain skeletal muscle relaxation during prolonged surgery or assisted respiration.a b 0.015 mg/kg may be used to maintain relaxation for controlled respiration.b
Up to 0.16 mg/kg has been used; however, large doses may increase frequency and severity of tachycardia.b
Up to 0.16 mg/kg has been used; however, large doses may increase frequency and severity of tachycardia.b
Increased initial dosage may be required to achieve effective neuromuscular blockade; once blockade is established, duration of blockade may be prolonged.a (See Hepatic Impairment under Cautions.)
Careful and individualized dosing recommended.a (See Renal Impairment under Cautions.)
Increased initial dosage may be required to achieve effective neuromuscular blockade; once blockade is established, duration of blockade may be prolonged.a (See Biliary Disease under Cautions.)
Substantially increased doses may be required due to development of resistance.c (See Burn Patients under Cautions.)
Administer small test dose and monitor response.a (See Neuromuscular Disease under Cautions.)
Known hypersensitivity to pancuronium bromide or any ingredient in the formulation.a
Potential for severely compromised respiratory function and respiratory paralysis.c
Should be used only by individuals experienced in the use of neuromuscular blocking agents and in the maintenance of an adequate airway and respiratory support.a Facilities and personnel necessary for intubation, administration of oxygen, and assisted or controlled respiration should be immediately available.a
IV cholinesterase inhibitor (e.g., neostigmine, pyridostigmine, edrophonium) should be readily available.a (See Reversal of Neuromuscular Blockade under Dosage and Administration.)
Use with caution in patients with pulmonary impairment or respiratory depression.c
Possible profound neuromuscular blockade in patients with neuromuscular disease (e.g., myasthenia gravis, Eaton-Lambert syndrome).a
Reduce initial dosage; monitor response carefully with a peripheral nerve stimulator.a
Hypersensitivity reactions (bronchospasm, flushing, redness, hypotension, tachycardia) reported rarely.a
Resistance to therapy with neuromuscular blocking agents can develop in burn patients,c particularly those with burns over 25–30% or more of body surface area.c
Resistance generally becomes apparent ≥1 week after the burn, peaks ≥2 weeks after the burn, persists for several months or longer, and decreases gradually with healing.c
Consider possible need for substantially increased doses.c
Possible increased heart rate, arterial pressure, and cardiac output.a
Use not recommended in patients with preexisting tachycardia or in patients in whom minor elevation in heart rate is undesirable.b
Possible prolonged paralysis and/or muscle weakness and atrophy.a
Continuous monitoring of neuromuscular transmission recommended during neuromuscular blocking agent therapy in intensive care setting.c Do not administer additional doses before there is a definite response to nerve stimulation tests.c If no response is elicited, discontinue administration until a response returns.c
Possible delayed onset of action in patients with impaired circulation (e.g., cardiovascular disease, edema);a however, larger than usual doses are not recommended.a
Possible increased or decreased neuromuscular blockade in patients with electrolyte distrubances (e.g., adrenocortical insufficiency) or acid/base imbalances.a
Malignant hyperthermia is rarely associated with use of neuromuscular blocking agents and/or potent inhalation anesthetics.c Be vigilant for its possible development and prepared for its management in any patient undergoing general anesthesia.c
Possible airway or ventilatory problems in patients with severe obesity.a Use with caution.a
Possible slower onset and prolonged duration of neuromuscular blockade.a (See Elimination: Special Populations, under Pharmacokinetics and also see Patients with Biliary Disease under Dosage and Administration.)
Category C.a
Not known whether pancuronium is distributed into milk.j
Excessive salivation may occur during very light anesthesia.b
Clinically important methemoglobinemia reported rarely in premature neonates receiving pancuronium in combination with fentanyl and atropine for emergency anesthesia and surgery; however, direct causal relationship not established.a
Large amounts of benzyl alcohol (i.e., 100–400 mg/kg daily) have been associated with toxicity in neonates;a d e f g h i each mL of pancucronium bromide injection contains 10 mg of benzyl alcohol.a
Neonates (<1 month of age) are particularly sensitive to neuromuscular blocking agents;a administer test dose to determine responsiveness.a (See Pediatric Patients under Dosage and Administration.) Carefully consider risks and benefits of long-term therapy in neonates.a (See Intensive Care Setting under Cautions.)
Use with caution in geriatric or debilitated patients.a c
Possible slower onset and prolonged duration of neuromuscular blockade; use with caution.a (See Elimination: Special Populations, under Pharmacokinetics and also see Hepatic Impairment under Dosage and Administration.)
Possible prolonged neuromuscular blockade; use with caution in patients with poor renal perfusion or severe renal disease.a b (See Elimination: Special Populations, under Pharmacokinetics.)
Skeletal muscle weakness, slight elevation in pulse rate and excessive salivation.a c
Drug | Interaction | Comments |
|---|---|---|
Anesthetics, general (enflurane, halothane, isoflurane) | Increased potency of neuromuscular blockadea | Select pancuronium dosage at lower end of recommended initial range a |
Antidepressants, tricyclic | Possible ventricular arrhythmias in patients receiving tricyclic antiderpessants concomitantly with pancuronium and halothanea | Use with cautiona |
Anti-infective agents (aminoglycosides, bacitracin, polymyxins, tetracyclines) | Possible prolonged duration of neuromuscular blockadea | |
Magnesium salts | Possible increased neuromuscular blockadea | Reduce pancuronium dosage if necessary a |
Neuromuscular blocking agents, nondepolarizing (e.g., atracurium, vecuronium) | Increased potency of neuromuscular blockadea | Concomitant use not recommendeda |
Quinidine | Possible recurrence of paralysisa | |
Succinylcholine | Prior administration of succinylcholine may increase potency and prolong duration of neuromuscular blockadea | Allow effects of succinylcholine to subside before administering pancuroniuma |
Poorly absorbed from the GI tract.c
Onset of paralysis is dose related.b
Following IV administration of 0.06 mg/kg, clinically sufficient neuromuscular blockade occurs within 2–3 minutes.b
Duration of paralysis is dose related.b
Duration of clinically sufficient neuromuscular blockade induced by 0.06 mg/kg is about 35–45 minutes.b
Supplemental doses may increase magnitude and duration of neuromuscular blockade.b
Crosses the placenta in small amounts.b
Approximately 87% (mainly γ-globulin; albumin to a lesser extent).100 101 102 104 May be concentration dependent.101 103 104
Hepatic103 or renal105 impairment does not affect protein binding. Impaired hepatic or biliary function may increase volume of distribution.a
Undergoes limited biotransformation.b
Excreted principally in urine as unchanged drug and to a lesser extent in bile.a
Triphasic; terminal half-life is approximately 2 hours.b
Impaired renal or hepatic function or biliary disease may decrease clearance and prolong half-life.a
2–8°C.a
For information on systemic interactions resulting from concomitant use, see Interactions.
Compatible |
|---|
Dextrose 5% in sodium chloride 0.45 or 0.9% |
Dextrose 5% in water |
Ringer's injection, lactated |
Sodium chloride 0.9% |
Compatible |
|---|
Ciprofloxacin |
Verapamil HCl |
Compatible |
|---|
Aminophylline |
Cefazolin sodium |
Cefuroxime sodium |
Cimetidine HCl |
Co-trimoxazole |
Dobutamine HCl |
Dopamine HCl |
Epinephrine HCl |
Esmolol HCl |
Etomidate |
Fenoldopam mesylate |
Fentanyl citrate |
Fluconazole |
Gentamicin sulfate |
Heparin sodium |
Hetastarch in lactated electrolyte injection (Hextend) |
Hydrocortisone sodium succinate |
Isoproterenol HCl |
Levofloxacin |
Lorazepam |
Midazolam HCl |
Milrinone lactate |
Morphine sulfate |
Nitroglycerin |
Ranitidine HCl |
Sodium nitroprusside |
Vancomycin HCl |
Incompatible |
Diazepam |
Thiopental sodium |
Variable |
Propofol |
Produces skeletal muscle relaxation by causing a decreased response to acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle.c
Exhibits high affinity for ACh receptor sites and competitively blocks access of ACh to motor end-plate of myoneural junction; may affect ACh release.a c
Blocks the effects of both the small quantities of ACh that maintain muscle tone and the large quantities of ACh that produce voluntary skeletal muscle contraction; does not alter the resting electrical potential of the motor end-plate or cause muscular contractions.c
Produces little or no histamine release.b c
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses (e.g., cardiovascular disease, neuromuscular disease).a
Importance of informing patients of other important precautionary information.a (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Injection, for IV use only | 1 mg/mL* | Pancuronium Bromide Injection (with benzyl alcohol 1%) | Abbott, Baxter, Sicor |
2 mg/mL* | Pancuronium Bromide Injection (with benzyl alcohol 1%) | Abbott, Baxter, Sicor |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Only references cited for selected revisions after 1984 are available electronically.
100. Pavulon prescribing information. In: Huff BB, ed. Physicians’ desk reference. 42nd ed. Oradell, NJ: Medical Economics Company Inc; 1988:1491-3.
101. Thompson JM. Pancuronium binding by serum proteins. Anaesthesia. 1976; 31:219-27. [PubMed 59554]
102. Foldes FF, Derby A. Protein binding of atracurium and other short-acting neuromuscular blocking agents and their interaction with human cholinesterases. Br J Anaesth. 1983; 55:31-4S.
103. Duvaldestin P, Henzel D. Binding of tubocurarine, fazadinium, pancuronium and Org NC45 to serum proteins in normal man and in patients with cirrhosis. Br J Anaesth. 1982; 54:513-6. [PubMed 6122460]
104. Ramzan MI, Somogyi AA, Walker JS et al. Clinical pharmacokinetics of the non-depolarising muscle relaxants. Clin Pharmacokinet. 1981; 6:25-60. [IDIS 165379] [PubMed 7018787]
105. Wood M, Stone WJ, Wood AJJ. Plasma binding of pancuronium: effects of age, sex, and disease. Anesth Analg. 1983; 62:29-32. [IDIS 164399] [PubMed 6849508]
a. Baxter. Pancuronium bromide injection prescribing information. Deerfield, IL: 2003 Jun.
b. AHFS Drug Information 2004. McEvoy GK, ed. Pancuronium bromide. Bethesda, MD: American Society of Health-System Pharmacists; 2004:1313-4.
c. AHFS Drug Information 2004. McEvoy GK, ed. Neuromuscular blocking agents general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2004:1303-6.
d. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12:10-11. [PubMed 7188569]
e. Anon. Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982; 31:290-91. [IDIS 150868] [PubMed 6810084]
f. Gershanik J. Boecler B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982; 307:1384-8. [IDIS 160823] [PubMed 7133084]
g. Menon PA, Thach BT, Smith CH et al. Benzyl alcohol toxicity in a neonatal intensive care unit: incidence, symptomatology, and mortality. Am J Perinatol. 1984; 1:288-92. [PubMed 6440575]
h. Anderson CW, Ng KJ, Andresen B et al. Benzyl alcohol poisoning in a premature newborn infant. Am J Obstet Gynecol. 1984; 148:344-6. [IDIS 181207] [PubMed 6695984]
i. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. [IDIS 175725] [PubMed 6889041]
j. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1058-62.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1281-3.
Generic Name: azithromycin (Oral route)
ay-zith-roe-MYE-sin
In the U.S.
Available Dosage Forms:
Therapeutic Class: Antibiotic
Chemical Class: Macrolide
Azithromycin is used to treat certain bacterial infections in many different parts of the body. This medicine may mask or delay the symptoms of syphilis. It is not effective against syphilis infections.
Azithromycin belongs to the class of drugs known as macrolide antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections.
This medicine is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of azithromycin in children and infants 6 months of age and older. However, safety and efficacy have not been established in infants younger than 6 months of age.
Appropriate studies have not been performed on the relationship of age to the effects of azithromycin oral suspension and tablets to treat pharyngitis or tonsillitis in children younger than 2 years of age. Safety and efficacy have not been established.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of azithromycin in the elderly.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | B | Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus. |
Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
This section provides information on the proper use of a number of products that contain azithromycin. It may not be specific to Zithromax Z-Pak. Please read with care.
Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.
This medicine comes with a patient information leaflet. Read and follow the instructions carefully. Ask your doctor if you have any questions.
You may take Zithromax® oral liquid or tablets with or without food.
Shake well the bottle of Zithromax® oral liquid before each use. Measure your dose correctly with a marked measuring spoon, oral syringe, or medicine cup. The average household teaspoon may not hold the right amount of liquid.
Measure the extended-release oral liquid with a marked measuring spoon, syringe, or cup. You or your child must take this medicine within 12 hours after it has been mixed with water. It is best to take the extended-release oral liquid on an empty stomach or at least 1 hour before or 2 hours after a meal. If your child does not use all of the medicine in the bottle, throw it away after you give the dose.
Keep using this medicine for the full treatment time, even if you or your child feel better after the first few doses. Your infection may not clear up if you stop using the medicine too soon.
If you are taking aluminum or magnesium-containing antacids, do not take them at the same time that you take this medicine. These medicines may keep azithromycin from working properly.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Do not refrigerate or freeze the extended-release oral liquid. Throw away any unused liquid after your dose.
You may store the oral liquid at room temperature or in the refrigerator. Do not freeze the bottle. Do not keep the oral liquid for more than 10 days. Throw away any unused liquid after all doses are completed.
It is very important that your doctor check the progress of you or your child at regular visits to make sure this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.
If you or your child's symptoms do not improve within a few days, or if they become worse, check with your doctor.
This medicine may cause serious allergic reactions, including anaphylaxis, which can be life-threatening and require immediate medical attention. Call your doctor right away if you or your child have a rash; itching; hives; hoarseness; shortness of breath; trouble breathing; trouble swallowing; or any swelling of your hands, face, or mouth after you take this medicine.
Serious skin reactions can occur with this medicine. Stop using this medicine and check with your doctor right away if you or your child have blistering, peeling, or loosening of the skin; red skin lesions; severe acne or skin rash; sores or ulcers on the skin; or fever or chills while you are using this medicine.
Stop using this medicine and check with your doctor right away if you or your child have pain or tenderness in the upper stomach; pale stools; dark urine; loss of appetite; nausea; unusual tiredness or weakness; or yellow eyes or skin. These could be symptoms of a serious liver problem.
Azithromycin may cause diarrhea, and in some cases it can be severe. It may occur 2 months or more after you stop using this medicine. Do not take any medicine to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you or your child have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.
This medicine can cause changes in heart rhythms, such as a condition called QT prolongation. It may change the way your heart beats and cause fainting or serious side effects in some patients. Contact your doctor right away if you or your child have any symptoms of heart rhythm problems, such as fast, pounding, or irregular heartbeats.
If you or your child vomits within one hour of taking the extended-release oral liquid, call your doctor right away to see if more medicine is needed.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Zithromax Z-Pak side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Naproxen/Esomeprazole Delayed-Release Tablets contains a nonsteroidal anti-inflammatory drug (NSAID). It may cause an increased risk of serious and sometimes fatal heart and blood vessel problems (eg, a heart attack, stroke). The risk may be greater if you already have heart problems or if you take Naproxen/Esomeprazole Delayed-Release Tablets for a long time. Do not use Naproxen/Esomeprazole Delayed-Release Tablets right before or after bypass heart surgery.
Naproxen/Esomeprazole Delayed-Release Tablets may cause an increased risk of serious and sometimes fatal stomach ulcers and bleeding. Elderly patients may be at greater risk. This may occur without warning signs.
Treating rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis in certain patients at risk of developing stomach ulcers when using NSAIDs. It may also be used for other conditions as determined by your doctor.
Naproxen/Esomeprazole Delayed-Release Tablets are an NSAID and a proton pump inhibitor (PPI) combination. Exactly how the NSAID works is not known. It may block certain substances in the body that are linked to inflammation and pain. NSAIDs treat symptoms of pain and inflammation. The PPI works by decreasing the amount of acid produced in the stomach. This decreases the risk of developing an ulcer from using an NSAID.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Naproxen/Esomeprazole Delayed-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Naproxen/Esomeprazole Delayed-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Naproxen/Esomeprazole Delayed-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Naproxen/Esomeprazole Delayed-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Naproxen/Esomeprazole Delayed-Release Tablets.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; gas; headache; heartburn; nausea; stomach bloating or upset.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; wheezing); bloody or black, tarry stools; bone pain; chest, jaw, or left arm pain; confusion; dark urine; decreased consciousness; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; mental or mood changes (eg, depression); numbness of an arm or leg; one-sided weakness; red, swollen, blistered, or peeling skin (with or without fever); ringing in the ears; seizures; severe or persistent headache or dizziness; severe or persistent stomach pain or nausea; severe vomiting; shortness of breath; slurred speech; stiff neck; sudden or unexplained weight gain; swelling of the hands, legs, or feet; symptoms of liver problems (eg, dark urine, loss of appetite, pale stools, yellowing of the skin or eyes); trouble sleeping; trouble swallowing; unusual bruising or bleeding; unusual joint or muscle pain; unusual tiredness or weakness; urination problems (eg, decreased, difficult, or painful urination); vision or hearing changes; vomit that looks like coffee grounds.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include black, tarry stools; confusion; decreased coordination; decreased urination; fast heartbeat; flushing; loss of consciousness; seizures; severe nausea or stomach pain; severe or persistent dizziness, drowsiness, or headache; slow or difficult breathing; sluggishness; uncontrolled movements; unusual bleeding or bruising; unusual sweating; vision changes; vomiting that may or may not look like coffee grounds.
Store Naproxen/Esomeprazole Delayed-Release Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store in the original packaging until just before use. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Naproxen/Esomeprazole Delayed-Release Tablets out of the reach of children and away from pets.
This information is summary only. It does not contain all information about Naproxen/Esomeprazole Delayed-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Soak a cotton tipped applicator or pledget of cotton with Hemal. Apply to bleeding area with pressure until hemorrhage is arrested. (Note: Should a small dark coagulum appear, flush it awa with water. This will have no effect on hemostatic action.) Each gram contains Aluminum Chloride 250mg, Aqueous vehicle 750mg. Contains no Epinephrine.
super dent®
Hemal
Topical Hemostat Solution
1 oz. (30mL)
REF 951-4760
Rx Only
For Dental Use Only
Distributed by Darby Dental Supply, LLC. Jericho, NY 11753
| Superdent Hemal aluminum chloride solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| UNAPPROVED DRUG OTHER | 02/19/1963 | ||
| Labeler - Darby Dental Supply LLC (825137818) |
| Registrant - DSHealthcare (056296981) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| DENTSPLY Caulk | 083235549 | MANUFACTURE | |
Eledoisina may be available in the countries listed below.
Eledoisina (DCIT) is also known as Eledoisin (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Panalgorin may be available in the countries listed below.
Metamizole sodium anhydrous (a derivative of Metamizole) is reported as an ingredient of Panalgorin in the following countries:
International Drug Name Search
Paracetamol CF may be available in the countries listed below.
Paracetamol is reported as an ingredient of Paracetamol CF in the following countries:
International Drug Name Search
Praticilin may be available in the countries listed below.
Ampicillin is reported as an ingredient of Praticilin in the following countries:
International Drug Name Search
Paracotene may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Paracotene in the following countries:
Paracetamol is reported as an ingredient of Paracotene in the following countries:
International Drug Name Search
Rec.INN
0023651-95-8
C9-H11-N-O5
213
Treatment of Parkinson's disease
(-)-threo-3-(3,4-Dihydroxyphenyl)-L-serine
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Injectio Polocaini hydrochlorici may be available in the countries listed below.
Procaine hydrochloride (a derivative of Procaine) is reported as an ingredient of Injectio Polocaini hydrochlorici in the following countries:
International Drug Name Search
Diltiazem Hydrochloride (BANM, JAN, USAN) is known as Diltiazem in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| JAN | Japanese Accepted Name |
| USAN | United States Adopted Name |
Pipamperon-neuraxpharm may be available in the countries listed below.
Pipamperone dihydrochloride (a derivative of Pipamperone) is reported as an ingredient of Pipamperon-neuraxpharm in the following countries:
International Drug Name Search
Pritalinc may be available in the countries listed below.
Lincomycin is reported as an ingredient of Pritalinc in the following countries:
International Drug Name Search
Alkosalen may be available in the countries listed below.
Flumetasone 21-pivalate (a derivative of Flumetasone) is reported as an ingredient of Alkosalen in the following countries:
Salicylic Acid is reported as an ingredient of Alkosalen in the following countries:
International Drug Name Search
